<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="652">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152667</url>
  </required_header>
  <id_info>
    <org_study_id>Elbanna_001</org_study_id>
    <nct_id>NCT05152667</nct_id>
  </id_info>
  <brief_title>Ambispective Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin</brief_title>
  <official_title>Ambispective Comparative Cohort Study to Assess the Effect of Pretreatment With a Levonorgestrel-Releasing Intrauterine System Versus Oral Progestin on ICSI and Vitrified-Warmed Embryo Transfer Outcomes in Women With Adenomyosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wael Elbanna Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National research centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wael Elbanna Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study participants' relevant medical records will be collected and reviewed for the&#xD;
      retrospective subjects and after obtaining informed consent for the prospective subjects. The&#xD;
      study materials that will be used will include blood tests, transvaginal ultrasound and&#xD;
      magnetic resonance imaging (MRI). The study will involve two study arms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study participants' relevant medical records will be collected and reviewed for the&#xD;
      retrospective subjects and after obtaining informed consent for the prospective subjects. The&#xD;
      study materials that will be used will include blood tests, transvaginal ultrasound and&#xD;
      magnetic resonance imaging (MRI). The study will involve two study arms:&#xD;
&#xD;
      Arm 1: Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device&#xD;
      (LNG-IUS) and proceeding with the ICSI Arm 2: Women with adenomyosis pretreated with oral&#xD;
      progestin &quot;Dienogest&quot; and proceeding with the ICSI Primary and secondary key measurements&#xD;
      will be used in the study.&#xD;
&#xD;
      The primary measures will include:&#xD;
&#xD;
        -  Presence of intrauterine gestational sac at 12 weeks&#xD;
&#xD;
        -  Presence of fetal heart pulsation at 12 weeks&#xD;
&#xD;
      The secondary key measures will include:&#xD;
&#xD;
        -  Occurance of abortion in the 1st trimester&#xD;
&#xD;
        -  Appearance of ectopic pregnancy diagnosis by:&#xD;
&#xD;
      Ultrasound Serum β-HCG level Symptoms of pain and bleeding&#xD;
&#xD;
        -  Two serum β-HCG levels in 48hrs interval to emphasis biochemical pregnancy&#xD;
&#xD;
        -  Recording the the baseline characteristics of the study participants&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ongoing pregnancy</measure>
    <time_frame>up to 13 weeks gestation</time_frame>
    <description>- Recording the following for the two arms of the study: Presence of intrauterine gestational sac at 12 weeks Presence of fetal heart pulsation at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurance of abortion or ectopic</measure>
    <time_frame>up to 13 weeks gestation</time_frame>
    <description>Recording the following for the two arms of the study:&#xD;
Occurance of abortion in the 1st trimester Appearance of ectopic pregnancy diagnosis Two serum β-HCG levels in 48hrs interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording the baseline characteristics of the study participants</measure>
    <time_frame>Before study intervention</time_frame>
    <description>age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording the baseline characteristics of the study participants</measure>
    <time_frame>Before study intervention</time_frame>
    <description>BMI in kg/m^2</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Adenomyosis</condition>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device (LNG-IUS) and proceeding with the ICSI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Women with adenomyosis pretreated with oral progestin &quot;Dienogest&quot; and proceeding with the ICSI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>levonorgestrel-releasing intrauterine device (LNG-IUS)</intervention_name>
    <description>Intervention is administered proceeding the ICSI</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>oral progestin &quot;Dienogest&quot;</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include women with adenomyosis, proceeding with the ICSI and&#xD;
        pretreated with either:&#xD;
&#xD;
          1. levonorgestrel-releasing intrauterine device (LNG-IUS)&#xD;
&#xD;
          2. Oral progestin &quot;Dienogest&quot;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed using both the transvaginal ultrasound study (TVS) and MRI criteria&#xD;
&#xD;
               -  Main criteria for sonographic and MRI diagnosis of adenomyosis are:&#xD;
&#xD;
             The appearance of asymmetrical thickening of the myometrium Irregular cystic areas&#xD;
             within the myometrium Linear striations radiating out from the myometrium&#xD;
&#xD;
          2. Patients ≤42 years old at the time of starting ICSI cycle&#xD;
&#xD;
          3. Cryopreserved embryo transfer cycles&#xD;
&#xD;
          4. The presence of at least one good cryopreserved day 3 embryo.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Transfer of a poor-quality embryo (grades 3 or 4)&#xD;
&#xD;
          2. History of myomectomy&#xD;
&#xD;
          3. Pelvic ultrasound that showed the presence of uterine fibroids, a hydrosalpinx or&#xD;
             endometrial polyps (all known causes of implantation failure).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>42 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Wael Saad Saad El Banna El Banna, MD</last_name>
    <phone>+2 01227760402</phone>
    <email>dr.wael.ss.elbanna@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eslam Fathy Fathy, M.Sc.</last_name>
    <phone>01092586140</phone>
    <email>eslam.f486@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wael Elbanna Clinic</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wael Elbanna, consultant</last_name>
      <phone>01227760402</phone>
      <email>waelelbanna@drwaelelbanna.com</email>
    </contact>
    <contact_backup>
      <last_name>manal elhinnawi, specialist</last_name>
      <phone>01007970546</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>November 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 27, 2021</last_update_submitted>
  <last_update_submitted_qc>November 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wael Elbanna Clinic</investigator_affiliation>
    <investigator_full_name>Wael Elbanna</investigator_full_name>
    <investigator_title>Managing director for Wael Elbanna Clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dienogest</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

